2022 pharma predictions – where are we now? - European Medical Journal

2022 pharma predictions – where are we now?

Season 02: episode 10

In celebration of the halfway point of the season, GOLD is going back to the start. As 2022 began, we asked a whole host of our former guests to pick out their predictions for the year ahead.

In this week’s episode, Helena and Assistant Editor Isabel O’Brien check in on some of the predictions from Julie Ross, President, Advanced Clinical; Kay Wesley, CEO, Kanga Health; and Jennifer Cain Birkmose, Vice President and Global Head of Patient Access and Community Engagement, SOBI, to see just how accurate they were, and what further work is needed if they are yet to be hit. Predictions include the expansion of decentralised clinical trials, the continuation of hybrid events and a continued push towards partnerships and cross-company collaboration.

Marc and Helena are also back together in the studio for a roundup of the news in ‘Things you might have missed’. The pair zone in on a new pledge by EFPIA to reduce inequalities in patient access to medicines across Europe, high-profile recent appointments and much more.

A little more on GOLD’s guests…

Julie Ross is President of Advanced Clinical and is a long-time active member of Healthcare Businesswoman’s Association (HBA), currently serving as Vice Chair of the Global Board. With over 25 years of clinical research experience, Julie has participated in fundraising, mergers and acquisitions, authored many clinical research articles and is a well-known industry speaker. Julie is a graduate of the University of Wisconsin, LaCrosse with a bachelor’s degree in Nuclear Medicine Technology and she received the coveted HBA Chair Award in 2019 and the PharmaVoice 100 Red Jacket award in 2020.

Kay Wesley is CEO of Kanga Health and has 20 years’ experience in and with the pharmaceutical industry, as well as non-pharma digital business leadership experience as a ‘dot com’ leader in the 1990s. She is also known as a thought leader in healthcare digital communications. Kay created and led AstraZeneca’s award-winning global digital marketing team for five years and then built a digital agency as part of a top three agency group before going on to launch Kanga Health as an independent business.

Jennifer Cain Birkmose is Vice President and Global Head of Patient Access and Community Engagement at SOBI. She has an incredibly abundant background in the pharmaceutical industry, public health and academia. Prior to joining SOBI, Jennifer led market access in Europe at Roche, emerging markets for Novartis and market access in EMEA for Janssen. Prior to joining the pharmaceutical industry, Jennifer worked in Copenhagen and Brussels for the European Regional Office of the World Health Organization. Jennifer has also worked in Washington for PAHO and the World Bank and is now based in Basel, Switzerland.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally